Liver cancer: Risk factors and prevention

Cancer Risk Assessment

Volumn , Issue , 2005, Pages 621-646

  Loffredo, Christopher ^a   Frank, Christina ^b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85031373473     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (161)

1. Niederhuber J. Tumors of the liver. In: Murphy G, Lawrence WJ, Lenhard R, eds. Amerian Cancer Society Textbook of Clinical Oncology. Atlanta, GA:American Cancer Society, 1995:269-280.
2. London W, McGlynn K. Liver cancer. In: Schottenfeld D, Fraumeni JJ, eds. Cancer Epidemiology and Prevention. 2nd ed. New York: Oxford University Press, 1996:772-793.
3. American Cancer Society. Cancer Facts and Figures 2000. Atlanta, GA:American Cancer Society Inc., 2000.
4. Tanaka K, Hirohata T, Fukuda K, Shibata A, Tsukuma H, Hiyama T. Risk factors for hepatocellular carcinoma among Japanese women. Cancer Causes Control 1995; 6:91-98.
5. Lui W, Lin H, Chau G, Liu T, Chi C. Male predominance in hepatocellular carcinoma: new insight and a possible therapeutic alternative. Med Hypotheses 2000; 55:348-350.
6. Purcell RH. Hepatitis viruses: changing patterns of human disease. Proc Natl Acad Sci USA 1994; 91:2401-2406.
7. Harsch HH, Pankiewicz J, Bloom AS, et al. Hepatitis C virus infection in cocaine users-a silent epidemic [In Process Citation]. Community Ment Health J 2000; 36:225-233.
8. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90:1562-1569.
9. Stuver SO. Towards global control of liver cancer? Semin Cancer Biol 1998; 8:299-306.
10. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54:594-614.
11. Parkin D, Ziegler J. Malignant diseases. In: Strickland G, ed. Hunter’s Tropical Medicine and Emerging Infectious Diseases. Part 1. Clinical Practice in the Tropics. 8th ed. Philadelphia: W.B. Saunders Co., 2000:94-107.
12. Higginson J, Muir CS, Munoz N. Human Cancer: Epidemiology and Environmental Causes. Cambridge: Cambridge University Press, 1992.
13. Kew MC. Hepatitis B and C viruses and hepatocellular carcinoma. Clin Lab Med 1996; 16:395-406.
14. Sallie R, Di Bisceglie AM. Viral hepatitis and hepatocellular carcinoma. Gastroenterol Clin North Am 1994; 23:567-579.
15. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2:1129-1133.
16. Lai CL, Gregory PB, Wu PC, Lok AS, Wong KP, Ng MM. Hepatocellular carcinoma in Chinese males and females. Possible causes for the male predominance. Cancer 1987; 60:1107-1110.
17. Yu MC, Tong MJ, Govindarajan S, Henderson BE. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 1991; 83:1820-1826.
18. Yu MW, Chen CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 1993; 53:790-794.
19. Tanaka K, Sakai H, Hashizume M, Hirohata T. Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 2000; 60:5106-5110.
20. Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down’s syndrome, leukemia, and hepatitis. Ann Intern Med 1967; 66:924-931.
21. Chazouilleres O, Mamish D, Kim M, et al. “Occult” hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994; 343:142-146.
22. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341:22-26.
23. Sagnelli E, Coppola N, Scolastico C, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000; 32:1106-1110.
24. Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week [letter]. Lancet 1981; 1:550-551.
25. Mondelli M, Vergani GM, Alberti A, et al. Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol 1982; 129:2773-2778.
26. Ganem D. Persistent infection of humans with hepatitis B virus: mechanisms and consequences. Rev Infect Dis 1982; 4:1026-1047.
27. Alward WL, McMahon BJ, Hall DB, Heyward WL, Francis DP, Bender TR. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985; 151:604-609.
28. Buendia MA. Hepatitis B viruses and hepatocellular carcinoma. Adv Cancer Res 1992; 59:167-226.
29. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118:554-559.
30. Donato F, Tagger A, Chiesa R, et al. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study. Hepatology 1997; 26:579-584.
31. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85:2132-2137.
32. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28:930-938.
33. Borzio M, Trere D, Borzio F, et al. Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Pathol 1998; 51:96-101.
34. Shibata M, Morizane T, Uchida T, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 1998; 351:1773-1777.
35. Caselmann WH. Transactivation of cellular gene expression by hepatitis B viral proteins: a possible molecular mechanism of hepatocarcinogenesis. J Hepatol 1995; 22:34-37.
36. Henkler FF, Koshy R. Hepatitis B virus transcriptional activators: mechanisms and possible role in oncogenesis. J Viral Hepat 1996; 3:109-121.
37. Buendia MA, Pineau P. The complex role of hepatitis B virus in human hepatocarcinogenesis. In: Barbanti-Brodano G, Bendinelli M, Friedman H, eds. DNA Tumor Viruses. New York: Plenum Press, 1995:171-193.
38. Luber B, Arnold N, Sturzl M, et al. Hepatoma-derived integrated HBV DNA causes multi-stage transformation in vitro. Oncogene 1996; 12:1597-1608.
39. Butel JS, Lee TH, Slagle BL. Is the DNA repair system involved in hepatitis-Bvirus- mediated hepatocellular carcinogenesis? Trends Microbiol 1996; 4:119-124.
40. Becker SA, Lee TH, Butel JS, Slagle BL. Hepatitis B virus X protein interferes with cellular DNA repair. J Virol 1998; 72:266-272.
41. Jia L, Wang XW, Harris CC. Hepatitis B virus X protein inhibits nucleotide excision repair. Int J Cancer 1999; 80:875-879.
42. Feitelson MA, Zhu M, Duan LX, London WT. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993; 8:1109-1117.
43. Slagle BL, Zhou YZ, Butel JS. Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinomas. Cancer Res 1991; 51:49-54.
44. Koike K, Moriya K, Yotsuyanagi H, Iino S, Kurokawa K. Induction of cell cycle progression by hepatitis B virus HBx gene expression in quiescent mouse fibroblasts. J Clin Invest 1994; 94:44-49.
45. Shibata Y, Nakata K, Tsuruta S, et al. Detection of hepatitis B virus X-region DNA in liver tissue from patients with hepatitis C virus-associated cirrhosis who subsequently developed hepatocellular carcinoma. Int J Oncol 1999; 14:1153-1156.
46. Poussin K, Dienes H, Sirma H, et al. Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas. Int J Cancer 1999; 80:497-505.
47. Yu MW, Pai CI, Yang SY, et al. Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: impact of smoking on risk. Gut 2000; 47:703-709.
48. Jaitovitch-Groisman I, Fotouhi-Ardakani N, Schecter RL, Woo A, Alaoui-Jamali MA, Batist G. Modulation of glutathione S-transferase alpha by hepatitis B virus and the chemopreventive drug oltipraz. J Biol Chem 2000; 275:33395-33403.
49. Van Damme P, Tormans G, Beutels P, Van Doorslaer E. Hepatitis B prevention in Europe: a preliminary economic evaluation. Vaccine 1995; 13:S54-S57.
50. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336:1855-1859.
51. Kane MA. World-wide status of hepatitis B vaccination 1998. Soz Praventivmed 1998; 43:S44-S46, S118-S120.
52. Zuckerman AJ. More than third of world’s population has been infected with hepatitis B virus. Br Med J 1999; 318:1213.
53. Vail BA. Management of chronic viral hepatitis. Am Fam Physician 1997; 55:2749-2756, 2759-2761.
54. Lai CL, Ching CK, Tung AK, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo- controlled trial. Hepatology 1997; 25:241-244.
55. Dusheiko G. Lamivudine therapy for hepatitis B infection. Scand J Gastroenterol Suppl 1999; 230:76-81.
56. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial [see comments]. Gut 2000; 46:562-568.
57. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359-362.
58. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244:362-364.
59. Okamoto H, Okada S, Sugiyama Y, et al. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 50-noncoding region. Jpn J Exp Med 1990; 60:215-222.
60. Cha TA, Kolberg J, Irvine B, et al. Use of a signature nucleotide sequence of hepatitis C virus for detection of viral RNA in human serum and plasma. J Clin Microbiol 1991; 29:2528-2534.
61. Krawczynski K, Beach MJ, Bradley DW, et al. Hepatitis C virus antigen in hepatocytes: immunomorphologic detection and identification. Gastroenterology 1992; 103:622-629.
62. Cho SW, Hwang SG, Han DC, et al. In situ detection of hepatitis C virus RNA in liver tissue using a digoxigenin-labeled probe created during a polymerase chain reaction. J Med Virol 1996; 48:227-233.
63. Fong TL, Shindo M, Feinstone SM, Hoofnagle JH, Di Bisceglie AM. Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. J Clin Invest 1991; 88:1058-1060.
64. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258:135-140.
65. Lai ME, Mazzoleni AP, Argiolu F, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994; 343:388-390.
66. Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66:3225-3229.
67. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321:1494-1500.
68. Pistello M, Ceccherini-Nelli L, Cecconi N, Bendinelli M, Panicucci F. Hepatitis C virus seroprevalence in Italian haemophiliacs injected with virus-inactivated concentrates: five year follow-up and correlation with antibodies to other viruses. J Med Virol 1991; 33:43-46.
69. Murphy EL, Bryzman SM, Glynn SA, et al. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology 2000; 31:756-762.
70. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86:655-661.
71. Moyer AL, Alter MJ. Hepatitis C virus in the hemodialysis setting: a review with recommendations for control. Sem Dial 1994; 7:124-127.
72. Mitsui T, Iwano K, Masuko K, et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992; 16:1109-1114.
73. Kiyosawa K, Sodeyama T, Tanaka E, et al. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med 1991; 115:367-369.
74. Dienstag JL. Sexual and perinatal transmission of hepatitis C. Hepatology 1997; 26:66S-70S.
75. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26:62S-65S.
76. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334:1691-1696.
77. Abdel-Aziz F, Habib M, Mohamed MK, et al. Hepatitis C virus (HCV) infection in a community in the nile delta: population description and HCV prevalence. Hepatology 2000; 32:111-115.
78. Khan AJ, Luby SP, Fikree F, et al. Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. Bull World Health Organ 2000; 78:956-963.
79. World Health Organisation. Hepatitis C-global prevalence (update). Wkly epidemial Rec 2000; 75:18-19.
80. Bendinelli M, Vatteroni ML, Maggi F, Pistello M. Hepatitis C virus. In:Specter S, ed. Viral Hepatitis. Totowa, NJ: Humana Press, 1999:65-127.
81. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 1995; 122:161-168.
82. IARC. Hepatitis viruses. IARC Monogr Eval Carcinog Risks Hum 1994; 59:1-255.
83. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12:671-675.
84. Hasan F, Jeffers LJ, De Medina M, et al. Hepatitis C-associated hepatocellular carcinoma. Hepatology 1990; 12:589-591.
85. Nishioka K, Watanabe J, Furuta S, et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991; 67:429-433.
86. Resnick RH, Koff R. Hepatitis C-related hepatocellular carcinoma. Prevalence and significance. Arch Intern Med 1993; 153:1672-1677.
87. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463-472.
88. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis:time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47:131-136.
89. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion- associated hepatitis C. N Engl J Med 1995; 332:1463-1466.
90. Butel JS. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcingenesis 2000; 21:405-426.
91. De Mitri MS, Poussin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet 1995; 345:413-415.
92. Kubo S, Nishiguchi S, Hirohashi K, et al. Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer 1999; 86:793-798.
93. Hoshiyama A, Kimura A, Fujisawa T, Kage M, Kato H. Clinical and histologic features of chronic hepatitis C virus infection after blood transfusion in Japanese children. Pediatrics 2000; 105:62-65.
94. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341:866-870.
95. Luban N, Post J, Glymph C. Transfusion associated hepatitis C and G in pediatric patients identified through a universal look-back approach. Transfusion 1999; 106 (suppl.):110S.
96. Locasciulli A, Testa M, Pontisso P, et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood 1997; 90:4628-4633.
97. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995; 23:8-12.
98. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alpha-resistant chronic hepatitis C. Gastroenterology 1994; 107:812-817.
99. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26:122S-127S.
100. Pozzato G, Kaneko S, Moretti M, et al. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. J Med Virol 1994; 43:291-296.
101. Yabuuchi I, Imai Y, Kawata S, et al. Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma. Liver 2000; 20:290-295.
102. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131:174-181.
103. Tanaka H, Tsukuma H, Kasahara A, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000; 87:741-749.
104. Toyoda H, Kumada T, Nakano S, et al. The effect of retreatment with interferon- alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Cancer 2000; 88:58-65.
105. Kasahara A, Hayashi N, Mochizuki K, et al. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradi-cation, as a result of interferon therapy. J Viral Hepat 2000; 7:343-351.
106. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon- alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051-1055.
107. Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer 2000; 89:53-59.
108. Tagger A, Donato F, Ribero ML, et al. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 1999; 81:695-699.
109. Kew MC, Yu MC, Kedda MA, Coppin A, Sarkin A, Hodkinson J. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 1997; 112:184-187.
110. Yu MC, Yuan JM, Ross RK, Govindarajan S. Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles County, California. Hepatology 1997; 25:226-228.
111. Tanaka K, Ikematsu H, Hirohata T, Kashiwagi S. Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection. J Natl Cancer Inst 1996; 88:742-746.
112. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75:347-354.
113. Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000; 46:420-426.
114. Tamura I, Kurimura O, Koda T, et al. Risk of liver cirrhosis and hepatocellular carcinoma in subjects with hepatitis B and delta virus infection: a study from Kure, Japan. J Gastroenterol Hepatol 1993; 8:433-436.
115. Boschi-Pinto C, Stuver S, Okayama A, et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis 2000; 181:35-41.
116. Okayama A, Maruyama T, Tachibana N, et al. Increased prevalence of HTLV-I infection in patients with hepatocellular carcinoma associated with hepatitis C virus. Jpn J Cancer Res 1995; 86:1-4.
117. Kamihira S, Yamada Y, Sohda H, et al. Human T-lymphotropic virus type-I influence on hepatotropic virus infections and the subsequent development of hepatocellular carcinoma. Cancer Detect Prev 1994; 18:329-334.
118. Stuver SO, Okayama A, Tachibana N, Tsubouchi H, Mueller NE, Tabor E. HCV infection and liver cancer mortality in a Japanese population with HTLV-I. Int J Cancer 1996; 67:35-37.
119. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995; 9:1131-1136.
120. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999; 179:1254-1258.
121. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26:1-5.
122. IARC. Alcohol drinking. Biological data relevant to the evaluation of carcinogenic risk to humans. IARC Monogr Eval Carcinog Risks Hum 1988; 44:101-152.
123. Yu H, Harris RE, Kabat GC, Wynder EL. Cigarette smoking, alcohol consumption and primary liver cancer: a case-control study in the USA. Int J Cancer 1988; 42:325-328.
124. Lieber CS, Baraona E, Leo MA, Garro A. International Commission for Protection against Environmental Mutagens and Carcinogen. ICPEMC Working Paper No. 15/2. Metabolism and metabolic effects of ethanol, including interaction with drugs, carcinogens and nutrition. Mutat Res 1987; 186:201-233.
125. Lieber CS, Seitz HK, Garro AJ, Worner TM. Alcohol-related diseases and carcinogenesis. Cancer Res 1979; 39:2863-2886.
126. Austin H, Delzell E, Grufferman S, et al. A case-control study of hepatocellular carcinoma and the hepatitis B virus, cigarette smoking, and alcohol consumption. Cancer Res 1986; 46:962-966.
127. Mirkin IR, Remington PL, Moss M, Anderson H. Liver cancer in Wisconsin:the potential for prevention. Wis Med J 1990; 89:49-53.
128. Khan KN, Yatsuhashi H. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients. Alcohol Alcohol 2000; 35:286-295.
129. Wong NA, Rae F, Simpson KJ, Murray GD, Harrison DJ. Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol Pathol 2000; 53:88-93.
130. Groopman JD, Wild CP, Hasler J, Junshi C, Wogan GN, Kensler TW. Molecular epidemiology of aflatoxin exposures: validation of aflatoxin-N7-guanine levels in urine as a biomarker in experimental rat models and humans. Environ Health Perspect 1993; 99:107-113.
131. Knight LP, Primiano T, Groopman JD, Kensler TW, Sutter TR. cDNA cloning, experssion activity of a second human aflatoxin B1-metabolizing member of the aldo-keto reductase superfamily AKR7A3. Carcinogenesis 1999; 20:1215-1223.
132. McGlynn KA, Rosvold EA, Lustbader ED, et al. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci USA 1995; 92:2384-2387.
133. Wild CP, Yin F, Turner PC, et al. Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia. Int J Cancer 2000; 86:1-7.
134. Neal GE, Eaton DL, Judah DJ, Verma A. Metabolism and toxicity of aflatoxins M1 and B1 in human-derived in vitro systems. Toxicol Appl Pharmacol 1998; 151:152-158.
135. Bosch F, Munoz N. Prospects for epidemiological studies on hepatocellular cancer as a model for assessing viral and chemical interactions. In: Bartsch H, Hemminki K, O’Neill I, eds. Methods for Detecting DNA Damaging Agents in Humans: Applications in Cancer Epidemiology and Prevention. IARC Scientific Publications No. 89. Lyon: International Agency for Research on Cancer, 1988:427-438.
136. Chen CJ, Wang LY, Lu SN, et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996; 24:38-42.
137. Ross RK, Yuan JM, Yu MC, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma [see comments]. Lancet 1992; 339:943-946.
138. Yu MW, Lien JP, Liaw YF, Chen CJ. Effects of multiple risk factors for hepatocellular carcinoma on formation of aflatoxin B1-DNA adducts. Cancer Epidemiol Biomarkers Prev 1996; 5:613-619.
139. Yu MW, Chiang YC, Lien JP, Chen CJ. Plasma antioxidant vitamins, chronic hepatitis B virus infection and urinary aflatoxin B1-DNA adducts in healthy males. Carcinogenesis 1997; 18:1189-1194.
140. Qian GS, Ross RK, Yu MC, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People’s Republic of China [see comments]. Cancer Epidemiol Biomarkers Prev 1994; 3:3-10.
141. Zhang BC, Zhu YR, Wang JB, et al. Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People’s Republic of China. J Cell Biochem Suppl 1997; 29:166-173.
142. Wang JS, Shen X, He X, et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People’s Republic of China. J Natl Cancer Inst 1999; 91:347-354.
143. Pirastu R, Comba P, Reggiani A, Foa V, Masina A, Maltoni C. Mortality from liver disease among Italian vinyl chloride monomer/polyvinyl chloride manufacturers. Am J Ind Med 1990; 17:155-161.
144. Lelbach WK. A 25-year follow-up study of heavily exposed vinyl chloride workers in Germany. Am J Ind Med 1996; 29:446-458.
145. Kielhorn J, Melber C, Wahnschaffe U, Aitio A, Mangelsdorf I. Vinyl chloride:still a cause for concern. Environ Health Perspect 2000; 108:579-588.
146. Sirica AE, Wilkerson CS, Wu LL, Fitzgerald R, Blanke RV, Guzelian PS. Evaluation of chlordecone in a two-stage model of hepatocarcinogenesis: a significant sex difference in the hepatocellular carcinoma incidence. Carcinogenesis 1989; 10:1047-1054.
147. Hayashi PH, Zeldis JB. Molecular biology of viral hepatitis and hepatocellular carcinoma. Compr Ther 1993; 19:188-196.
148. Sterling TD, Arundel A. Review of recent Vietnamese studies on the carcinogenic and teratogenic effects of phenoxy herbicide exposure. Int J Health Serv 1986; 16:265-278.
149. Cordier S, Le TB, Verger P, et al. Viral infections and chemical exposures as risk factors for hepatocellular carcinoma in Vietnam. Int J Cancer 1993; 55:196-201.
150. Austin H, Delzell E, Grufferman S, et al. Case-control study of hepatocellular carcinoma, occupation, and chemical exposures. J Occup Med 1987; 29:665-669.
151. Soliman AS, Smith MA, Cooper SP, et al. Serum organochlorine pesticide levels in patients with colorectal cancer in Egypt. Arch Environ Health 1997; 52:409-415.
152. Trichopoulos D, Day NE, Kaklamani E, et al. Hepatitis B virus, tobacco smoking and ethanol consumption in the etiology of hepatocellular carcinoma. Int J Cancer 1987; 39:45-49.
153. La Vecchia C, Negri E, Decarli A, D’Avanzo B, Franceschi S. Risk factors for hepatocellular carcinoma in northern Italy. Int J Cancer 1988; 42:872-876.
154. Mohamed AE, Kew MC, Groeneveld HT. Alcohol consumption as a risk factor for hepatocellular carcinoma in urban southern African blacks. Int J Cancer 1992; 51:537-541.
155. Peters M, Wellek S, Dienes HP, et al. Epidemiology of hepatocellular carcinoma. Evaluation of viral and other risk factors in a low-endemic area for hepatitis B and C. Z Gastroenterol 1994; 32:146-151.
156. Chen CJ, Liang KY, Chang AS, et al. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology 1991; 13:398-406.
157. Tanaka K, Sakai H, Hashizume M, Hirohata T. A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis. Jpn J Cancer Res 1998; 89:1241-1250.
158. Mori M, Hara M, Wada I, et al. Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol 2000; 151:131-139.
159. Wang LY, Chen CJ, Zhang YJ, et al. 4-Aminobiphenyl DNA damage in liver tissue of hepatocellular carcinoma patients and controls. Am J Epidemiol 1998; 147:315-323.
160. Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000; 85:498-502.
161. Mukaiya M, Nishi M, Miyake H, Hirata K. Chronic liver diseases for the risk of hepatocellular carcinoma: a case-control study in Japan. Etiologic association of alcohol consumption, cigarette smoking and the development of chronic liver diseases. Hepatogastroenterology 1998; 45:2328-2332.